The stock of Intersect ENT Inc (NASDAQ:XENT) is a huge mover today! About 140,946 shares traded hands. Intersect ENT Inc (NASDAQ:XENT) has declined 39.30% since April 18, 2016 and is downtrending. It has underperformed by 43.73% the S&P500.
The move comes after 8 months positive chart setup for the $330.88M company. It was reported on Nov, 18 by Barchart.com. We have $28.61 PT which if reached, will make NASDAQ:XENT worth $456.61 million more.
Intersect ENT Inc (NASDAQ:XENT) Ratings Coverage
Out of 7 analysts covering Intersect ENT (NASDAQ:XENT), 5 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 71% are positive. Intersect ENT has been the topic of 8 analyst reports since August 17, 2015 according to StockzIntelligence Inc. The rating was initiated by Bank of America with “Buy” on Friday, December 18. JP Morgan downgraded the shares of XENT in a report on Wednesday, November 2 to “Neutral” rating. The rating was initiated by Northland Capital on Tuesday, March 29 with “Outperform”. The rating was initiated by Deutsche Bank on Thursday, October 6 with “Hold”. On Tuesday, September 29 the stock rating was maintained by Piper Jaffray with “Overweight”. Canaccord Genuity maintained the shares of XENT in a report on Thursday, October 1 with “Buy” rating. The stock has “Buy” rating given by Canaccord Genuity on Monday, August 17.
According to Zacks Investment Research, “Intersect ENT, Inc. is a commercial drug-device company. The Company’s initial products, PROPEL and PROPEL mini, are drug-eluting implants for use in patients with chronic sinusitis. It offers products and therapies for ear, nose, and throat surgeons to improve treatment for their patients with chronic diseases. Intersect ENT, Inc. is headquartered in Menlo Park, California.”
Another recent and important Intersect ENT Inc (NASDAQ:XENT) news was published by Businesswire.com which published an article titled: “Intersect ENT to Present at the Piper Jaffray 28th Annual Healthcare Conference” on November 15, 2016.
XENT Company Profile
Intersect ENT, Inc., incorporated on October 6, 2003, is a commercial stage drug-device company. The Firm develops drugs for patients with ear, nose and throat (ENT) conditions. The Firm has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.